Mass drug administration

Administer disease-appropriate medicine across an eligible target population without requiring a positive individual diagnosis, while keeping exclusions, uptake, and outcomes program-specific.

Version

v1 · 2026-10-07 · History

Domain-specific #

13939

Domain group

Applied Sciences & Engineering

Origin domain

Medicine & Healthcare

Subdomains

Public Health, Infectious Disease Control → Medicine & Healthcare

Aliases

MDA

Core Idea

Mass drug administration (MDA) is a campaign that offers a disease-appropriate medicine to eligible people in a defined target population without requiring each person to have a positive diagnosis, and actually administers treatment to participating eligible people. The target, eligibility exclusions, medicine, and objective belong to the specific disease and program. The offer can be broad even when not everyone participates or completes treatment; measured coverage and health effects are separate questions.[^{ref-fc1f915ccf45][}ref-926668c7932a][^ref-481826e87086]

Scope of Application

The same rule appears in a Southern Zambia malaria trial and a Fiji community scabies trial. In Zambia, eligible residents in the MDA arm were offered dihydroartemisinin plus piperaquine regardless of rapid-test result, though testing still occurred. In Fiji, mass permethrin and mass ivermectin arms treated participating community residents, with topical permethrin offered to some people ineligible for ivermectin. The medicines, exclusions, and measured endpoints differed.[^{ref-926668c7932a][}ref-481826e87086]

Clarity

Keep target population, people eligible for a regimen, people offered it, people actually treated, and people whose disease outcome changed distinct. “Mass” does not mean literally every resident receives the same medicine. “Without individual diagnosis” means a positive test does not gate the population offer; testing may still be used for other reasons. An announced offer with no medicine administered has not yet performed MDA.[^{ref-fc1f915ccf45][}ref-926668c7932a]

Manages Complexity

The campaign can be analyzed through a few roles: defined population, medicine-specific eligibility, status-independent offer, actual administration, declared public-health aim, and separate evaluation of uptake and outcomes. This map prevents a particular drug, round count, or delivery method from being mistaken for the identity. WHO's 2017 malaria manual distinguishes transmission reduction from morbidity-and-mortality reduction, illustrating that even objectives must be named rather than assumed.[^ref-fc1f915ccf45]

Abstract Reasoning

To classify a program, ask whether it selects a population rather than only diagnosed patients, whether test positivity is required for the offer, what exclusions apply to the chosen medicine, and whether treatment was delivered. To evaluate it, then measure reach and adherence and compare disease outcomes over a stated time window. Successful delivery does not by itself establish transmission interruption or lasting benefit.[^{ref-fc1f915ccf45][}ref-926668c7932a]

Knowledge Transfer

The role map transfers within infectious-disease control from malaria to scabies, but every disease needs its own medicine, eligibility and outcome evidence. A large nonmedical rollout is an analogy, not a literal MDA instance. The current typed catalog has no approved all-instance parent for the complete medicine-campaign identity; this entry is an approved unparented root.[^{ref-926668c7932a][}ref-481826e87086]

Example

In the Southern Zambia trial, sixty health-facility catchment areas were randomized among community MDA, focal MDA, and control groups. The MDA arm offered DHAp to eligible residents irrespective of their rapid-test results and administered two rounds. Infants under three months and first-trimester pregnant women were excluded from that regimen. The researchers measured household-team coverage and five-month malaria outcomes, which varied by endpoint and transmission stratum. The example supplies a defined target, eligibility rule, diagnosis-independent offer, actual treatment, aim, and separate evaluation; it does not prove universal efficacy or a current drug recommendation.[^ref-926668c7932a]

Neighborhood in Abstraction Space

Mass drug administration sits in a sparse region of the domain-specific corpus (100^th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.

Family — Unclustered & Miscellaneous (2551 abstractions)

Nearest neighbors

• Convenience Sampling — 0.74
• Clinical Study Design — 0.74
• Translational Research — 0.73
• Random Digit Dialing — 0.73
• Clinical-Trial Stratification — 0.73

Computed from structural-signature embeddings · 2026-10-08

Not to Be Confused With

Screen-and-treat requires a positive individual test before the campaign medicine is offered. Focal MDA can treat household members after one household member tests positive; the Zambia study distinguishes this from its community-wide MDA arm. Ordinary case management treats diagnosed or suspected patients and contacts. None of these selection rules is identical to a population-wide diagnosis-independent offer. Population health can assess a campaign's outcomes but is not the administration campaign itself.[^{ref-926668c7932a][}ref-481826e87086]

References

[^ref-fc1f915ccf45]: World Health Organization. Mass drug administration for falciparum malaria: a practical field manual. 2017. Executive summary, printed pp. ix–x; §1.2, printed p. 1.

[^ref-926668c7932a]: Thomas P. Eisele et al. “Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial.” The Journal of Infectious Diseases 214 (2016): 1831–1839. DOI 10.1093/infdis/jiw416. Methods, Study Design and Participants, Randomization, Interventions; Results and Abstract. https://academic.oup.com/jid/article/214/12/1831/2632617

[^ref-481826e87086]: Lucia Romani et al. “Mass Drug Administration for Scabies Control in a Population with Endemic Disease.” New England Journal of Medicine 373 (2015): 2305–2313. DOI 10.1056/NEJMoa1500987. Study Procedures, printed p. 2307; Interventions, printed pp. 2308–2309; Results, printed pp. 2309–2310. https://uploads-ssl.webflow.com/6142c52b847e7ea0f5639451/6188a5ce2ccdfe36bf615bc7_Romani-New-England-Journal-of-Medicine-2015.pdf